Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II photodynamic therapy with talaporfin sodium and diode laser for malignant spinal cord tumor
jRCT2021220040Phase 2Active, not recruiting
- Start
- Jan 2023
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talaporfin sodium in spinal cord cancer and spinal glioma. Primary endpoint: Survival rate at 12 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
talaporfin sodium
03
Conditions
spinal cord cancerspinal glioma
Beyond the preview
Go deeper on jRCT2021220040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220040.